Investment Analysts’ Weekly Ratings Changes for Biohaven (BHVN)

Several brokerages have updated their recommendations and price targets on shares of Biohaven (NYSE: BHVN) in the last few weeks:

• 6/29/2026 – Biohaven was given a new $11.00 price target by Needham & Company LLC.
• 6/29/2026 – Biohaven had its “underperform” rating reaffirmed by Bank of America Corporation. They now have a $11.00 price target on the stock, down from $12.00.
• 6/27/2026 – Biohaven was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 6/26/2026 – Biohaven had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft.
• 6/2/2026 – Biohaven had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 5/27/2026 – Biohaven had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc..
• 5/26/2026 – Biohaven had its “neutral” rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
• 5/13/2026 – Biohaven had its price target lowered by Morgan Stanley from $21.00 to $18.00. They now have an “overweight” rating on the stock.
• 5/5/2026 – Biohaven had its price target lowered by Royal Bank Of Canada from $23.00 to $22.00. They now have an “outperform” rating on the stock.

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.